Page 18 - Cassava Sciences News Today

New York, USA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsight The Alzheimer's disease market size is

In this piece, we will take a look at the top 12 small-cap stocks with the highest upside potential.

NEW ORLEANS, July 07, 2023 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick...

Cassava Sciences, Inc. (NASDAQ:SAVA – Free Report)’s share price traded up 2.4% on Thursday . The company traded as high as $22.59 and last traded at $22.56. 856,684 shares were traded during trading, a decline of 13% from the average session volume of 986,435 shares. The stock had previously closed at $22.04. Cassava Sciences Trading […]

Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.Drug Effects Favored Mild...

SAVA | Complete Cassava Sciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.Drug Effects Favored Mild Alzheimer’s Disease.In Mild...

Cassava Sciences Inc (NASDAQ: SAVA) announced topline clinical results from its Cognition Maintenance Study (CMS), a small proof-of-concept study designed to demonstrate the effects of simufilam versus placebo in a 

Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading lower Wednesday.

Shares of Cassava Sciences, Inc. (SAVA) are slipping over 14% on Wednesday morning. SAVA is currently trading at $21.66, down $3.66 or 14.45%, on the Nasdaq. The stock opened its trading at $26.